Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

C-RAD, Audiocast with teleconference, Q3'24

By Inderes10/23/2024, 9:00 AM
C-Rad

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Cecilia de Leeuw
00:01 - 07:21

Welcome to our Q3 presentation. We had a challenging quarter, but let me start by zooming out a bit. Let me briefly take you through Sieradz's long-term strategy and our progress for Q3. Sieradz is active in the field of radiation therapy, and approximately half of all cancer patients receive radiation therapy as part of their treatment; we continue to invest in our world-leading products. Sieradz is in a very strong position with our entire portfolio interfacing all major LINACs, Protons, and CT vendors. This is our most extensive interoperability portfolio ever. Sieradz already today has a global reach, but we are constantly looking into market expansions. And we do this step by step. Growing our global presence is strengthening Sieradz's resilience. And in the third quarter, we continue to see the result of our enhanced focus on the less mature Southeast Asian markets. We are ramping up our investment in Latin America, where we had a successful training in connection with Astro, the med tech show, for the Latin American distributors. And why is that important? Sieradz sees an untapped potential in many markets, which we want to capture at the right time. This quarter, we had several US retrofit wins on Varian LINACs, and it's important to us for two reasons. Number one, addressing the LINACs that do not yet have Surface Guided Radiation Therapy or SGRT. And number two: strengthening our position in the US market. And finally, Sieradz has good financial stability. And for this quarter we have displayed solid profitability despite the headwinds in the EMEA region, while we are simultaneously investing for growth. So let's take a look at our Q3 numbers. We ended the third quarter with an order intake of 100 million MSEK, a decline of 40%, or 38% in constant currencies from an unusually strong Q3 '23. And clearly, this is below our expectations. The weak performance in EMEA could not be compensated by the strong performance in APAC, nor by the performance in the Americas during the quarter. While we had eight quarters of very strong revenue growth, in the third quarter, we are down 10% from the same quarter last year, or 7% in constant currencies with revenue of 100 million CC. This is mainly driven by lower order intake and the timing of our backlog. However, it should be noted that this is our fifth consecutive quarter with revenue exceeding 100 million SEK. And as I just mentioned, we continue to build market resilience, preparing our sales readiness for selected emerging markets. The sales cycles in our business are long, so we must prepare ourselves well ahead of time. And despite the headwinds, we have a solid EBIT margin of 17%. The order backlog of 735 million SEK is on the same level as in the third quarter of last year. So let's look into the regional performance in the quarter. As I already mentioned, EMEA had another challenging quarter. Order intake decreased 77% to 23 million SEK. It is a very tough comparison. And you might recall that we received three unusually large orders in Q3 last year. The main factor is the macroeconomic slowdown in Germany and continued slower decision-making. And this is indeed true for service contract extensions in EMEA. There have been fewer large tenders for the first three quarters of the year. Middle East, an emerging market for us, is moving slower and decision-making is taking longer than initially expected, impacted by the geopolitical situation. Revenue decreased 41% to 32 million SEK, affected by a lower order intake and a slower backlog conversion. Without a doubt, however, there is untapped potential in advanced markets. There are also regional highlights with good performance in Central Eastern Europe for this quarter. But as I already said, this is below our expectation. So what are we doing? We have increased our market activity with targeted sales campaigns, attending local trade shows, intensifying our marketing efforts, and expanding our activities in the retrofit markets. In addition, we are proactively reaching out to existing customers to ensure that we are on top of their clinical training needs, and staying close to our customers is beneficial to us as they are important references for new business opportunities. For the Americas, we had good progress in the quarter. Order intake increased by 10% to 28 million SEK, while revenue declined by 10% to 23 million SEK. Our long-term focus on strengthening our position in the US market by increasing our focus on the Varian install base is starting to pay off. We had some good wins on Varian LINACs this quarter, and Latin America is on the rise. Latin America is a market where the number of LINACs per million is only two, versus the W.H.O. recommendation of four LINACs per million inhabitants. recommendation of four LINACs per million inhabitants. And putting this into perspective, the number for the US is twelve. An indication of this potential is that after the closing of the quarter, we received a 10 million SEK order in Mexico. And lastly, the APAC region continued to perform well in the quarter. Order intake was up 11% to 48 million SEK, and revenue increased 43% to $45 million. There is large unmet demand in Southeast Asia. And we see, in fact, more and more tenders, including SGRT from the start. Australia continues to invest in SGRT, and our position in this advanced market is very strong. Japan is also contributing to the strong performance in the quarter, and last year, we secured our first service contracts in China and added more contracts this quarter. And with that, over to you, Linda, for a closer look at the financials.

Linda Frölén
07:22 - 09:52

Thank you, Cecilia. So regarding the Q3 financials, I will take you through some of the main events that have shaped our Q3 financials with main focus on gross margin, opex levels, EBIT margin, and cash flow. Gross profit for the quarter was 72.7 million SEK, compared to 72.0 million a year ago. This corresponds to a margin of 73% versus 65% last year. The margin in the third quarter was positively affected by mixed effects from a larger-than-normal proportion of Protons orders that were delivered and settled during Q3, but were also impacted by settlements. Regarding Proton orders delivered during Q2. Regarding our main operating expenses, you see on the left-hand side of the chart that they have slightly increased year on year, from 51.7 million last year to 53.7 million in this quarter. The increase is mainly due to higher consultancy costs within central functions, which are partly offset by lower bonus expenses connected to the lower order intake and revenue. At the right-hand side of the chart, we see that quarter on quarter OpEx is down from 68 million in Q2 to 53.7 million in this quarter. The decrease is related to lower personnel and consultancy costs due to summer holidays, but also lower bonus expenses. EBIT for the third quarter was 17.4 million, compared to 18.9 million a year ago. And looking back a few quarters, we see improved earnings and a healthy EBIT margin, paving the way for investments for growth in the future. Regarding Protons orders delivered during Q2. Cash at quarter end stood at 118.7 million, compared to 142 million at the beginning of the quarter. The main driver behind the decrease in cash flow from working capital, which was negatively affected during the quarter, was mainly due to increased receivables from delivered Proton orders, which are settled only after completed final acceptance tests. And also note that Seerad is a company with a strong balance sheet and no long-term debt. And with that, I will hand it back to Cecilia for a summary.

Cecilia de Leeuw
09:54 - 11:02

Thank you, Linda. And before moving into Q&A, let me summarize. With our leading portfolio. We are 100% committed to continuing our fight against cancer. It has been a challenging quarter with macroeconomic headwinds, despite good progress in APAC and the Americas. Could this quarter not compensate for the slowdown in EMEA? It is still early days, and we see untapped potential in both advanced and emerging markets, and the growing installed base of our products out there is an opportunity for future service contracts. We continuously improve our global reach and are working hard to ensure that our very strong offering is known to all clinics out there. And finally, our profitability and balance sheet are strong, which gives us the opportunity to both innovate in our products and expand into new markets. And with that, operator, we are now ready for questions.

Operator
11:08 - 11:33

If you wish to ask a question, please dial pound five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound six on your telephone keypad. Please ask a maximum of two questions. The next question comes from Christian Lee from Pareto Securities. Please go ahead.

Christian Lee
11:35 - 11:38

Thank you. I hope you can hear me.

Cecilia de Leeuw
11:39 - 11:41

Yes, we can. Hey, Christian.

Christian Lee
11:41 - 12:00

Okay, great. Hi. I was thinking about the gross margin, which has been at very high levels in the last two quarters due to the delivery of Protons orders. How should we think about the gross margin in Q4? Do you have any orders left to deliver in the fourth quarter?

Linda Frölén
12:02 - 12:38

Uh. Hi, Christian. We do have Proton orders in our order backlog. The timing of when they will be delivered is something that we don't have any information about right now. Typically, the underlying gross margin will be around 73 to 70%. Uh, sorry, 63 to 65%, but it will be boosted in the quarters where we have Proton deliveries, whether or not they will happen in Q4. It's too early to say.

Christian Lee
12:42 - 13:05

Okay. Thank you. And, I was also thinking about your working capital, which has been tied up due to the delivered Protons orders. When do you expect the acceptance test to be completed? And could it be possible to disclose the amount that has been tied up? Thank you.

Unknown 1
13:07 - 13:08

Um.

Linda Frölén
13:09 - 13:35

The timing of the final acceptance test varies from customer to customer, so it's a bit difficult to say. The amount that is tied up in this quarter—the working capital effect—is more or less fully explained by the Protons orders. So without giving an exact number.

Unknown 1
13:35 - 13:36

That is how you should see it.

Linda Frölén
13:36 - 13:38

That is how you should see it.

Christian Lee
13:41 - 13:55

Okay. So, could you give us some indication if you expect the tied-up working capital to be freed up in the fourth quarter already, or should it? Should we expect that to happen next year?

Linda Frölén
13:55 - 14:05

Regarding the Protons orders, I cannot comment. I cannot confirm that, but one of my main focuses as the new CFO is, of course, to manage the balance sheet.

Christian Lee
14:08 - 14:10

Okay. Perfect. Thank you very much.

Cecilia de Leeuw
14:11 - 14:12

Thank you very much.

Operator
14:18 - 14:23

The next question comes from Mikael Jacobson at Ratus. Please unmute your microphone.

Unknown 2
14:24 - 14:25

Can you hear me?

Cecilia de Leeuw
14:26 - 14:27

Yes, yes.

Unknown 2
14:28 - 14:50

Uh, hi. Um, I have a question here. In the middle of September, you gave a private presentation at an Investor Day, whereupon your stock price crashed. It now seems likely that you provided those investors with asymmetrical information, allowing them to front-run your other investors by selling first. Do you understand how inappropriate that would be?

Cecilia de Leeuw
14:51 - 15:08

Yeah. So, the information from the investor conference was nothing new. It was known information. And whatever was picked up by the reporter and how that was presented, that needs to stand for him.

Unknown 2
15:09 - 15:13

But you do understand that the optics of this are terrible for you.

Cecilia de Leeuw
15:15 - 15:29

As I said, the information was nothing new. How it was picked up and presented or displayed in the heading by the reporter must be accounted for by him.

Unknown 3
15:29 - 15:30

Yeah.

Unknown 2
15:30 - 15:40

I mean, I don't know what was said in that private meeting because it was a private presentation. But this is devastating for investor confidence. I just wanted you to be aware of that.

Cecilia de Leeuw
15:41 - 15:43

Mika, did you have more questions?

Unknown 2
15:43 - 15:45

No. That was it for me. Okay.

Cecilia de Leeuw
15:45 - 15:46

Thank you.

Operator
15:54 - 16:19

As a reminder, if you wish to ask a question, please dial the pound key followed by five on your telephone keypad. There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.

Cecilia de Leeuw
16:23 - 16:37

Thank you all for attending our Q3 presentation. We are making a real difference to cancer patients around the world, and our fight against cancer continues. Thank you all very much.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…